

Publication list

Sumitomo R, Hirai T, **Fujita M**, Murakami H, Otake Y, Huang CL. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. *Lung Cancer*. 2019 Aug 31;136:136-144

Yagita M, Hata S, Miyata H, Kakita H, Tsukamoto T, Muso E, **Fujita M**. Systemic Lupus Erythematosus Associated with Ovarian Cancer. *Intern Med*. 2019 Mar 1;58(5):731-735.

Fujita, M., P. Davari, Y.K. Takada, and Y. Takada, *Stromal cell-derived factor-1 (CXCL12) activates integrins by direct binding to an allosteric ligand-binding site (site 2) of integrins without CXCR4*. *Biochem J*, 2018. **475**(4): p. 723-732.
10.1042/BCJ20170867

Nakano Y, Yamamoto M, Komatsu K, Yagita M, **Fujita M**. Hypertrophic Pachymeningitis in Sjögren's Syndrome. *Intern Med*. 2018 Feb 1;57(3):413-415.

Takada, Y.K., J. Yu, M. **Fujita, J.** Saegusa, C.Y. Wu, and Y. Takada, *Direct binding to integrins and loss of disulfide linkage in interleukin-1beta (IL-1beta) are involved in the agonistic action of IL-1beta*. *J Biol Chem*, 2017. **292**(49): p. 20067-20075.
10.1074/jbc.M117.818302

Takada, Y., Y.K. Takada, and **M. Fujita**, *Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1*. *Cytokine Growth Factor Rev*, 2017. **34**: p. 67-72. 10.1016/j.cytogfr.2017.01.003

Takashima R, Takamatsu K, Shinkawa Y, Yagita M, Fukui M, **Fujita M**. Dermatomyositis Associated with Lung Neuroendocrine Carcinoma. *Intern Med*. 2017;56(6):719-724.

Fujita M, Nakano Y, Yagita M. Successful treatment of prokinetic-resistant intestinal pseudo-obstruction and pneumatosis cystoides intestinalis in systemic sclerosis with metronidazole. *Rheumatol Int*. 2017 Jul;37(7):1213-1215.

Takada, Y. and **M. Fujita**, *Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner*. Adv Exp Med Biol, 2017. **925**: p. 103-115. 10.1007/5584_2016_95

Fujita M, Tabuchi Y, Yagita M. Successful treatment of refractory giant cell arteritis with etanercept. Rheumatol Int. 2016 Aug;36(8):1177-9.

Yagita M, Tsujimoto K, Yagita M, **Fujita M**. Atypical Presenting Symptoms of Acute Onset Systemic Lupus Erythematosus with Enteritis and Cystitis. Case Rep Med. 2016;2016:8579812

Tsujimoto K, Yagita M, Taniguchi M, **Fujita M**. Successful Use of Plasma Exchange in the Treatment of Corticosteroid-Refractory Eosinophilic Granulomatosis with Polyangiitis Associated with Gastrointestinal Manifestations. Case Reports Immunol. 2016;2016:8341751

Shinkawa Y, Yagita M, **Fujita M**. Myocarditis in Mixed Connective Tissue Disease: A Case Report. J Clin Case Rep 2016, 6: 679

Yagita M, Hamano T, Hatachi S, **Fujita M**. Peripheral neuropathies during biologic therapies. Mod Rheumatol. 2016;26(2):288-93

Fujita, M., K. Zhu, C.K. Fujita, M. Zhao, K.S. Lam, M.J. Kurth, Y.K. Takada, and Y. Takada, *Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins $\alpha v\beta 3$, $\alpha 4\beta 1$, and $\alpha 5\beta 1$* . J Biol Chem, 2015. **290**(1): p. 259-71. 10.1074/jbc.M114.579946

Fujita, M., Y.K. Takada, and Y. Takada, *The Chemokine Fractalkine Can Activate Integrins without CX3CR1 through Direct Binding to a Ligand-Binding Site Distinct from the Classical RGD-Binding Site*. PLoS One, 2014. **9**(5): p. e96372. 10.1371/journal.pone.0096372

Fujita, M., Y.K. Takada, Y. Izumiya, and Y. Takada, *The Binding of Monomeric C-Reactive Protein (mCRP) to Integrins $\alpha v\beta 3$ and $\alpha 4\beta 1$ Is Related to Its Pro-Inflammatory Action*. PLoS One, 2014. **9**(4): p. e93738. 10.1371/journal.pone.0093738

Fujita, M. and Y. Takada, *Integrins as Co-receptors of Fractalkine*. Austin Journal of Clinical Immunology, 2014. **1**(3).

Ye, L., T. Dickerson, H. Kaur, Y.K. Takada, **M. Fujita**, R. Liu, J.M. Knapp, K.S. Lam, N.E. Schore, M.J. Kurth, and Y. Takada, *Identification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin alphavbeta3*. Bioorg Med Chem Lett, 2013. **23**(1): p. 340-5. 10.1016/j.bmcl.2012.10.080

Mori, S., V. Tran, K. Nishikawa, T. Kaneda, Y. Hamada, N. Kawaguchi, **M. Fujita**, Y.K. Takada, N. Matsuura, M. Zhao, and Y. Takada, *A Dominant-Negative FGF1 Mutant (the R50E Mutant) Suppresses Tumorigenesis and Angiogenesis*. PLoS One, 2013. **8**(2): p. e57927. 10.1371/journal.pone.0057927

Fujita, M., Y.K. Takada, and Y. Takada, *Insulin-like Growth Factor (IGF) Signaling Requires alphavbeta3-IGF1-IGF Type 1 Receptor (IGF1R) Ternary Complex Formation in Anchorage Independence, and the Complex Formation Does Not Require IGF1R and Src Activation*. J Biol Chem, 2013. **288**(5): p. 3059-69. 10.1074/jbc.M112.412536

Fujita, M., K. Ieguchi, D.M. Cedano-Prieto, A. Fong, C. Wilkerson, J.Q. Chen, M. Wu, S.H. Lo, A.T. Cheung, M.D. Wilson, R.D. Cardiff, A.D. Borowsky, Y.K. Takada, and Y. Takada, *An Integrin Binding-defective Mutant of Insulin-like Growth Factor-1 (R36E/R37E IGF1) Acts as a Dominant-negative Antagonist of the IGF1 Receptor (IGF1R) and Suppresses Tumorigenesis but Still Binds to IGF1R*. J Biol Chem, 2013. **288**(27): p. 19593-603. 10.1074/jbc.M113.470872

Fujita, M., Y.K. Takada, and Y. Takada, *Integrins alphavbeta3 and alpha4beta1 Act as Coreceptors for Fractalkine, and the Integrin-Binding Defective Mutant of Fractalkine Is an Antagonist of CX3CR1*. J Immunol, 2012. **189**(12): p. 5809-5819. 10.4049/jimmunol.1200889

Fujita, M., K. Ieguchi, P. Davari, S. Yamaji, Y. Taniguchi, K. Sekiguchi, Y.K. Takada, and Y. Takada, *Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions*. J Biol Chem, 2012. **287**(15): p. 12491-500. 10.1074/jbc.M111.304170

Yamaji, S., J. Saegusa, K. Ieguchi, **M. Fujita**, Y.K. Takada, and Y. Takada, *A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist*. PLoS One, 2010. **5**(4): p. e10273. 10.1371/journal.pone.0010273

Ieguchi, K., **M. Fujita**, Z. Ma, P. Davari, Y. Taniguchi, K. Sekiguchi, B. Wang, Y.K. Takada, and Y. Takada, *Direct binding of the EGF-like domain of neuregulin-1 to integrins ($\alpha_v\beta_3$ and $\alpha_6\beta_4$) is involved in neuregulin-1/ErbB signaling*. J Biol Chem, 2010. **285**(41): p. 31388-98. M110.113878 [pii] 10.1074/jbc.M110.113878

Misaki K, Morinobu A, Saegusa J, Kasagi S, **Fujita-M**, Miyamoto Y, Matsuki F, Kumagai S. *Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice*. Arthritis Res Ther. 13(3):R77.

Fujita-M, Hatachi-S, Yagita-M, *Acute Chlamydiae pneumoniae infection in the pathogenesis of autoimmune diseases Lupus*. 2009;18(2):164-8.

Fujita-M, Komatsu-K, Hatachi-S, Yagita-M. *Reversible posterior leukoencephalopathy syndrome in a patient with Takayasu arteritis*. Mod Rheumatol. 2008;18(6):623-9.

Fujita-M, Hatachi-S, Yagita-M *Dermatomyositis associated with thyroid cancer*. Rheumatol Int 2008;29(2):203-5

Hata-A, **Fujita-M**, Morishima-T, Kumakura-A, Hata-D. *Acute cerebellar ataxia associated with primary human herpesvirus-6 (HHV-6) infection: a report of two cases*. Journal of Paediatrics and Child Health 2008;44:10:607-609

Fujita-M, Hatachi-S, Yagita-M. *Immunohistochemically proven cytomegalovirus gastrointestinal diseases in three patients with autoimmune diseases*. Clin Rheumatol. 2008;27(8):1057-9

Fujita-M, Sugiura-R, Lu-Y, Xu-L, Xia-Y, Shuntoh-H, Kuno-T. *Genetic interaction between calcineurin and type 2 myosin and their involvement in the regulation of cytokinesis and chloride ion homeostasis in fission yeast*. Genetics, 2002 Jul; 161: 971-81

Cheng-H, Sugiura-R, Wu-W, **Fujita-M**, Lu-Y, Sio-SO,Takegawa-K, Shuntoh-H, Kuno-T. *Role of the Rab GTP-binding protein Ypt3 in the fission yeast exocytic pathway,and its connection to calcineurin function.* Mol-Biol-Cell, 2002 Aug; 13:2963-76

Fujita-M, Tamegai-H, Eguchi-T, Kakinuma-K. *Novel substrate specificity of designer 3-isopropylmalate dehydrogenase derived from Thermus thermophiles HB8.*Biosci Biotechnol Biochem. 2001 Dec;65(12):2695-700

Fujita-M, Toyooka-Y, Tamegai-H, Eguchi-T, Kakinuma-K. *Arg-94 is crucial to the catalysis of 3-isopropylmalate dehydrogenase from Thermus thermophilus HB8.* *Journal of Molecular Catalysis B: Enzymatic*, 2000 April; 9, 21:149-155